Novartis’s Phase 3 HORIZON trial found pelacarsen sharply lowered lipoprotein(a) yet, over almost five years, did not reduce heart attacks, strokes, urgent coronary revascularization, or death versus placebo. Details were presented Saturday at the American Heart Association scientific sessions in Ch